Amylyx Pharmaceuticals, Inc. (AMLX) /
The debt of Amylyx Pharmaceuticals, Inc. over the past 5 years
Chart Amylyx Pharmaceuticals, Inc.: liquid cash, total debt, net cash, fiscal 2021–2025 Open the chart →At the end of fiscal 2025, the latest fiscal year on file, Amylyx Pharmaceuticals, Inc. had liquid cash of $316.98M and total debt of $0: net cash of $316.98M. It had more liquid cash than debt at all 4 year-ends shown.
Year by year
| Fiscal year | Liquid cash | Total debt* | Net cash* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $316.98M* | $0 | $316.98M |
| 2024ended Dec 31, 2024 | $176.5M* | $0 | $176.5M |
| 2023ended Dec 31, 2023 | $371.36M* | $0 | $371.36M |
| 2022ended Dec 31, 2022 | $346.94M* | $0 | $346.94M |
| 2021ended Dec 31, 2021 | — | — | — |
Fiscal years as Amylyx Pharmaceuticals, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Amylyx Pharmaceuticals, Inc.
- The revenue of Amylyx Pharmaceuticals, Inc.
- The profitability of Amylyx Pharmaceuticals, Inc.
- The cash flow of Amylyx Pharmaceuticals, Inc.
- All of Amylyx Pharmaceuticals, Inc.'s financials, charted
Companies of a similar size
- CLBTCellebrite DI Ltd.
- IMAXIMAX Corporation
- KNFKnife River Corporation
- AVAHAveanna Healthcare Holdings Inc.
- EEFTEURONET WORLDWIDE, INC.
Not investment advice. This page shows what Amylyx Pharmaceuticals, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.